TABLE 1.

Gadolinium Content in the Cerebellum, Cerebrum, Skin, and Blood

	One‐week Recovery	Two‐weeks Recovery	Three‐weeks Recovery	Five‐weeks Recovery
Cerebellum (nmol Gd/g)
Gadoteridol	0.693 ± 0.114	0.356 ± 0.043	0.223 ± 0.037	0.144 ± 0.025
n	15	15	15	15
Gadoterate	0.878 ± 0.130***	0.614 ± 0.083***	0.453 ± 0.097***	0.282 ± 0.061***
n	15	14	15	15
Gadobutrol	1.011 ± 0.187***	0.682 ± 0.100***	0.449 ± 0.104***	0.297 ± 0.059***
n	15	15	15	15
Cerebrum (nmol Gd/g)
Gadoteridol	0.675 ± 0.163	0.332 ± 0.052	0.212 ± 0.031	0.129 ± 0.024
n	15	15	15	15
Gadoterate	0.860 ± 0.092**	0.558 ± 0.063***	0.471 ± 0.047***	0.311 ± 0.042***
n	15	14	14	15
Gadobutrol	0.843 ± 0.156**	0.585 ± 0.098***	0.457 ± 0.072***	0.309 ± 0.052***
n	15	15	15	15
Skin (nmol Gd/g)
Gadoteridol	2.939 ± 0.854	0.694 ± 0.162	0.460 ± 0.079	0.305 ± 0.068
n	15	14	14	15
Gadoterate	9.744 ± 2.933***	2.651 ± 1.077***	1.791 ± 0.684***	0.525 ± 0.142***
n	15	15	15	14
Gadobutrol	8.799 ± 1.998***	2.328 ± 0.738***	1.582 ± 0.578***	0.518 ± 0.184***
n	15	15	15	15
Blood (nmol Gd/g)
Gadoteridol	0.284 ± 0.033	0.160 ± 0.016	0.106 ± 0.021	0.039 ± 0.006 a
n	15	15	15	15
Gadoterate	0.159 ± 0.024***	0.092 ± 0.008***	0.072 ± 0.009***	0.029 ± 0.005*** b
n	15	15	15	15
Gadobutrol	0.190 ± 0.026***,°°	0.126 ± 0.016***,°°°	0.087 ± 0.017**,°°	0.042 ± 0.005°°° c
n	15	15	15	15

Values presented as mean ± Standard Deviation (SD).

The significance of differences between groups is shown as *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. group 1 and °P ≤ 0.05; °°P ≤ 0.01; °°°P ≤ 0.001 vs. group 2.

Data for blood below the lower limit of quantification (LLOQ) were extrapolated.

^a 3/15 value below the quantification limit.

^b 10/15 values below the quantification limit.

^c 1/15 value below the quantification limit.